ZOETIS Inc. (NYSE: ZTS) closed Oct. 14, 2026, at $75.29, down 37.41 percent year-to-date. The animal health company now trades with a $31.11 billion market cap and a 52-week range of $68.77 to $148.30.
The selloff reflects a real shift in consumer behavior. Middle Coast Investing highlighted in its Q3 2026 letter that pet owners—particularly in the U.S.—are "trading down to not pay for the best of market treatments." The trend is visible across Zoetis' skincare portfolio, where premium products face volume headwinds as households tighten discretionary spending.
Zoetis supplies pharmaceuticals and diagnostics for companion animals and livestock, including dermatology treatments, vaccines, parasite control and pain management. Portela, a three-month injectable for arthritis pain in cats, exemplifies the premium-priced products now seeing lower adoption.
The competitive environment has intensified alongside demand weakness. Stalled growth and margin pressure from both rivals and cost inflation compound the challenge for a company that was spun from Pfizer in 2013.
yet hedge fund interest is rising. The number of hedge fund portfolios holding Zoetis climbed to 64 at the end of Q2 2026, up from 57 in Q1. That divergence—falling stock price but rising institutional ownership—suggests either conviction-based accumulation or index-driven buying masking the fundamental deterioration.
Middle Coast Investing does not rank Zoetis among its 40 Most Popular Stocks Among Hedge Funds, flagging that certain AI stocks offer greater upside with lower tail risk. The signal is clear: the market has better risk-reward bets available.
